Evidence map›Paper›PMID 41783980›Full record

ArticleLung cancer management2026

Addition of pulsed electric field ablation to SBRT for lung tumors: effect on health-related quality of life.

Jeremy P Harris, Christina Boyd, Mengying Shi, Michael Reilly, Aaron Simon, Steven N Seyedin, Wen-Pin Chen, Misako Nagasaka, Nadine Abi-Jaoudeh, Michael A Hoyt

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Lung cancer management, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Jeremy P HarrisDepartment of Radiation Oncology, University of California - Irvine, Orange, CA, USA.ORCID 0000-0001-7603-0263
Christina BoydDivision of Vascular & Interventional Radiology, University of California - Irvine, Orange, CA, USA.
Mengying ShiDepartment of Radiation Oncology, University of California - Irvine, Orange, CA, USA.
Michael ReillyDepartment of Radiation Oncology, University of California - Irvine, Orange, CA, USA.
Aaron SimonDepartment of Radiation Oncology, University of California - Irvine, Orange, CA, USA.
Steven N SeyedinDepartment of Radiation Oncology, University of California - San Francisco, San Francisco, CA, USA.
Wen-Pin ChenDepartment of Medicine, University of California - Irvine, Orange, CA, USA.
Misako NagasakaDivision of Hematology & Oncology, University of California - Irvine, Orange, CA, USA.
Nadine Abi-JaoudehDivision of Vascular & Interventional Radiology, University of California - Irvine, Orange, CA, USA.
Michael A HoytDepartment of Population Health & Disease Prevention, University of California Irvine - Irvine, Orange, CA, USA.

Funding

Univ.of Calif., Irvine Cancer Center Support GrantP30CA062203 · NCI · UNIVERSITY OF CALIFORNIA-IRVINE · PI Melanie Funes · 1994 to 2026
$57.9M
NCI NIH HHS P30 CA062203
6 · The paper itself

Abstract

introductionTreatment indications for oligometastatic/oligoprogressive lung tumors are growing. Safety and lack of detrimental effect on patients' quality of life are critical for novel local therapies.

methodsWe tested that the additive effect of pulsed electric field (PEF) ablation with lower-dose stereotactic body radiation therapy (SBRT) on health-related quality of life (HRQoL) as a secondary endpoint in a prospective clinical trial. FACT-Lung Cancer Subscale (FACT-LCS) and FACT-General domain surveys were collected at screening, 3 months, and 12 months. Functional clinical data included forced vital capacity (FVC), forced expiratory volume in one second (FEV1), and diffusing capacity of the lung for carbon monoxide (DLCO).

resultsSix patients with eight tumors were enrolled. Baseline well-being domain scores were: Physical 25.9 (Std Dev 2.3), Social 21.0 (Std Dev 6.9), Emotional 17.3 (Std Dev 4.7), Functional 21.2 (Std Dev 5.8), and LCS 19.4 (Std Dev 5.3). There were no significant changes following combined modality treatment in HRQoL domain scores or pulmonary function metrics after treatment. Lower EWB and SWB were associated with worse FVC and FEV1.

conclusionIn this small pilot study, no clinically meaningful declines in pulmonary function or patient-reported quality of life were observed at 3 months following combination therapy.

Indexed as

ablationcancerclinical trialslungmetastasisnovel therapyRadiation therapy

Identifiers

PMID41783980
PMCPMC12969734

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.